| 1 |
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
Stephen S Lim et al. · The Lancet
Open access209 authors |
Dec 2012 |
12,027 |
| 2 |
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
Andrew Rhodes et al. · Intensive Care Medicine
Open access |
18 Jan 2017 |
6,868 |
| 3 |
Comprehensive molecular characterization of gastric adenocarcinoma
Adam Joel Bass et al. · Nature
Open access258 authors |
23 Jul 2014 |
6,680 |
| 4 |
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Daniel J. Klionsky et al. · Autophagy
Open access2,467 authors |
2 Jan 2016 |
6,023 |
| 5 |
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Laura Evans et al. · Intensive Care Medicine
Open access |
2 Oct 2021 |
5,314 |
| 6 |
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Chetan Bettegowda et al. · Science Translational Medicine
Open access |
19 Feb 2014 |
5,211 |
| 7 |
Genetic effects on gene expression across human tissues
François Aguet et al. · Nature
Open access250 authors |
10 Oct 2017 |
4,762 |
| 8 |
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
Goodarz Danaei, Mariel McKenzie Finucane, Yuan Lu et al. · The Lancet
|
28 Jun 2011 |
3,607 |
| 9 |
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn et al. · New England Journal of Medicine
Open access |
17 Feb 2017 |
3,457 |
| 10 |
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
Jimmy Z. Liu et al. · Nature Genetics
Open access |
20 Jul 2015 |
2,805 |
| 11 |
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1
Daniel J. Klionsky et al. · Autophagy
Open access2,930 authors |
2 Jan 2021 |
2,743 |
| 12 |
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
5 Jun 2022 |
2,702 |
| 13 |
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert John Motzer et al. · New England Journal of Medicine
Open access |
16 Feb 2019 |
2,590 |
| 14 |
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
7 Dec 2011 |
2,559 |
| 15 |
Comprehensive genomic profiles of small cell lung cancer
Julie George et al. · Nature
Open access |
10 Jul 2015 |
2,448 |
| 16 |
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa et al. · New England Journal of Medicine
Open access |
4 Jul 2018 |
2,386 |
| 17 |
Genome-wide association study identifies novel breast cancer susceptibility loci
Douglas F. Easton et al. · Nature
Open access239 authors |
27 May 2007 |
2,342 |
| 18 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon‐Koo Kang et al. · The Lancet
Open access |
12 Oct 2017 |
2,317 |
| 19 |
Data Resource Profile: The Korea National Health and Nutrition Examination Survey (KNHANES)
Sun‐Seog Kweon, Yoonjung Kim, Minyoung Jang et al. · International Journal of Epidemiology
Open access |
Feb 2014 |
2,225 |
| 20 |
Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19)
Waleed A. Alhazzani et al. · Intensive Care Medicine
Open access |
28 Mar 2020 |
2,204 |
| 21 |
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
18 Feb 2015 |
2,183 |
| 22 |
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Jean Schlumberger, Makoto Tahara, Lori J. Wirth et al. · New England Journal of Medicine
Open access |
11 Feb 2015 |
2,109 |
| 23 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al. · New England Journal of Medicine
Open access |
11 Dec 2019 |
2,026 |
| 24 |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda et al. · New England Journal of Medicine
Open access |
31 May 2017 |
1,947 |
| 25 |
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
Richard S. Finn et al. · Journal of Clinical Oncology
|
2 Dec 2019 |
1,842 |
| 26 |
Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer
Yi-Long Lung Cancer Wu et al. · New England Journal of Medicine
Open access |
19 Sep 2020 |
1,809 |
| 27 |
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al. · New England Journal of Medicine
Open access |
20 Sep 2020 |
1,743 |
| 28 |
TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity
Michaela U. Gack, Young Chul Shin, Chul-Hyun Joo et al. · Nature
|
28 Mar 2007 |
1,725 |
| 29 |
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study
Jong‐Mu Sun et al. · The Lancet
Open access |
Aug 2021 |
1,679 |
| 30 |
Association analysis identifies 65 new breast cancer risk loci
Kyriaki Michailidou et al. · Nature
Open access362 authors |
20 Oct 2017 |
1,602 |
| 31 |
Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations
Jason Phua, Li Weng, Lowell Ling et al. · The Lancet Respiratory Medicine
Open access |
6 Apr 2020 |
1,580 |
| 32 |
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
Ghassan K. Abou‐Alfa et al. · NEJM Evidence
Open access |
6 Jun 2022 |
1,534 |
| 33 |
International Consensus Diagnostic Criteria for Autoimmune Pancreatitis
Tooru Shimosegawa, Suresh T. Chari, Luca Frulloni et al. · Pancreas
|
16 Mar 2011 |
1,529 |
| 34 |
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Scott Kopetz et al. · New England Journal of Medicine
Open access |
30 Sep 2019 |
1,500 |
| 35 |
Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Suspected Coronary Artery Disease
Bjarne Linde Nørgaard, Jonathon A Leipsic, Sara Gaur et al. · Journal of the American College of Cardiology
Open access |
31 Jan 2014 |
1,498 |
| 36 |
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al. · The Lancet
Open access |
21 Nov 2012 |
1,428 |
| 37 |
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
Fátima Cardoso et al. · Annals of Oncology
Open access |
23 Sep 2020 |
1,397 |
| 38 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara, Yung‐Jue Bang, Satoru Iwasa et al. · New England Journal of Medicine
Open access |
29 May 2020 |
1,352 |
| 39 |
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al. · The Lancet
Open access158 authors |
4 Jun 2018 |
1,338 |
| 40 |
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Alexander E. Perl et al. · New England Journal of Medicine
Open access |
30 Oct 2019 |
1,285 |
| 41 |
Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics
Alvaro Barbeira et al. · Nature Communications
Open access264 authors |
2 May 2018 |
1,265 |
| 42 |
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology
Open access |
30 Sep 2019 |
1,262 |
| 43 |
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri et al. · New England Journal of Medicine
Open access |
25 Sep 2015 |
1,248 |
| 44 |
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Thomas B. Powles, Jonathan E. Rosenberg, Guru Sonpavde et al. · New England Journal of Medicine
Open access |
12 Feb 2021 |
1,233 |
| 45 |
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture
Karol Estrada et al. · Nature Genetics
Open access180 authors |
15 Apr 2012 |
1,223 |
| 46 |
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
Robin Kate Kelley et al. · The Lancet
Open access216 authors |
16 Apr 2023 |
1,150 |
| 47 |
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth Ann Mittendorf, Hong Zhang, Carlos H. Barrios et al. · The Lancet
Open access |
20 Sep 2020 |
1,099 |
| 48 |
Esophageal motility disorders on high‐resolution manometry: Chicago classification version 4.0 ©
Rena H. Yadlapati et al. · Neurogastroenterology & Motility
Open access |
29 Dec 2020 |
1,079 |
| 49 |
International Consensus Guidance Statement on the Management and Treatment of IgG4‐Related Disease
Arezou Khosroshahi et al. · Arthritis & Rheumatology
|
25 Mar 2015 |
1,071 |
| 50 |
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin et al. · Journal of Clinical Oncology
Open access |
23 Oct 2023 |
1,055 |